Melinta Therapeutics (MLNT) versus OHR Pharmaceutical (OHRP) Critical Survey

OHR Pharmaceutical (NASDAQ:OHRP) and Melinta Therapeutics (NASDAQ:MLNT) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, institutional ownership, profitability, analyst recommendations, risk, valuation and dividends.

Analyst Ratings

This is a summary of current ratings and recommmendations for OHR Pharmaceutical and Melinta Therapeutics, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
OHR Pharmaceutical 0 0 0 0 N/A
Melinta Therapeutics 0 1 6 0 2.86

Melinta Therapeutics has a consensus target price of $62.92, suggesting a potential upside of 1,213.50%. Given Melinta Therapeutics’ higher probable upside, analysts plainly believe Melinta Therapeutics is more favorable than OHR Pharmaceutical.


This table compares OHR Pharmaceutical and Melinta Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
OHR Pharmaceutical N/A -74.77% -69.84%
Melinta Therapeutics -163.01% -60.83% -28.55%

Volatility and Risk

OHR Pharmaceutical has a beta of 1.2, indicating that its stock price is 20% more volatile than the S&P 500. Comparatively, Melinta Therapeutics has a beta of 2.22, indicating that its stock price is 122% more volatile than the S&P 500.

Valuation and Earnings

This table compares OHR Pharmaceutical and Melinta Therapeutics’ gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
OHR Pharmaceutical N/A N/A -$13.23 million N/A N/A
Melinta Therapeutics $96.43 million 0.56 -$157.19 million ($17.72) -0.27

OHR Pharmaceutical has higher earnings, but lower revenue than Melinta Therapeutics.


Melinta Therapeutics beats OHR Pharmaceutical on 6 of the 8 factors compared between the two stocks.

OHR Pharmaceutical Company Profile

OHR Pharmaceutical, Inc. operates as a development stage pharmaceutical company. The company intends to merge with NeuBase Therapeutics, Inc. that focuses on advancing NeuBase's peptide-nucleic acid antisense oligonucleotide technology platform for the development of therapies to address severe and currently untreatable diseases caused by genetic mutations. OHR Pharmaceutical, Inc. is headquartered in New York, New York.

Melinta Therapeutics Company Profile

Melinta Therapeutics, Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes various anti-infectives for the treatment of bacterial infectious diseases in North America. It offers Baxdela, a monotherapy treatment of adult patients with acute bacterial skin or skin structure infections (ABSSSIs); Vabomere, an IV antibiotic used in treatment of gram-negative infections; Orbactiv, an IV antibiotic of the lipoglycopeptide class for the treatment of adult patients with ABSSSIs; and Minocin, a IV antibiotic of the tetracycline class with activity against gram-positive and gram-negative pathogens. The company has license agreements with Yale University, Medical Research Council, Wakunaga Pharmaceutical Co., Ltd., and CyDex Pharmaceuticals, Inc. Melinta Therapeutics, Inc. was founded in 2000 and is headquartered in New Haven, Connecticut.

Receive News & Ratings for OHR Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OHR Pharmaceutical and related companies with's FREE daily email newsletter.